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osting by EAbstract Troponins are regulatory proteins that form the cornerstone of muscle contraction. The
amino acid sequences of cardiac troponins differentiate them from that of skeletal muscles, allowing
for the development of monoclonal antibody-based assay of troponin I (TnI) and troponin T (TnT).
Along with the patient history, physical examination and electrocardiography, the measurement of
highly sensitive and speciﬁc cardiac troponin has supplanted the former gold standard biomarker
(creatine kinase-MB) to detect myocardial damage and estimate the prognosis of patients with
ischemic heart disease. The current guidelines for the diagnosis of non-ST segment elevation
myocardial infarction are largely based on an elevated troponin level. The implementation of these
new guidelines in clinical practice has led to a substantial increase in the frequency of myocardial
infarction diagnosis.
Automated assays using cardiac-speciﬁc monoclonal antibodies to cardiac TnI and TnT are com-
mercially available. They play a major role in the evaluation of myocardial injury and prediction of
cardiovascular outcome in cardiac and non-cardiac causes.
In this review we discuss the clinical applications of cardiac troponins and the interpretation of
elevated levels in the context of various clinical settings.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.06276861.
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Cardiac muscle is similar to skeletal muscle which contains con-
tractile proteins, but cardiac muscles are branched and inter-
connected and lack the end plates and have involuntary control.
These contractile proteins compose of overlapping thick
and thin ﬁlaments which slide past each other to produce mus-1 Regulation of muscle contraction by troponin. TnC, TnI, an
boxyl terminus. Reproduction with permission from Hernandezcle contraction in an active process requiring large amounts of
oxygen which needs a rich capillary bed. The thick ﬁlament is
composed of myosin which contains adenosine triphosphatase
(ATPase) activity and forms cross-bridges with actin. The thin
ﬁlament consists of actin, tropomyosin and troponin regula-
tory complex which includes: troponin C (TnC) that binds
Ca2+ to initiate muscle contraction, troponin I (TnI) thatd TnT, tropomyosin C, I, and T, respectively. N, amino terminus;
et al. (2001).
The clinical signiﬁcance of cardiac troponins in medical practice 5inhibits actin-myosin coupling through the inhibition of
ATPase activity, while troponinT (TnT) binds to tropomyosin
and stabilizes the complex on the actin ﬁlament (Fig. 1) (Sacks,
1999; Hernandez et al., 2001).
Troponins are present in both skeletal and cardiac
muscles, but amino acid sequences are dissimilar allowing
differential detection by monoclonal antibody-based assay.
The majority of cardiac troponin is bound to myoﬁlaments
and the remainder is free in the cytosole in comparison to
CK-MB which is fully cytosolic. In myocyte damage, cyto-
solic pool is released ﬁrst. Cytosolic pool for TnT is 6–8%
of its total intracellular concentration while cytosolic pool
for TnI is 2.8% (Alpert et al., 2000). Troponin has two peaks
rendering it offers no advantage over CK-MB for early
diagnosis of MI. CK-MB has a baseline value that may blunt
the rapid rise and rapid clearance, while troponin has no
baseline value and has a slow clearance and cross-reactivity
of cardiac troponin with skeletal muscle is low (Neumayr
et al., 2001).
Creatine kinase-MB isoform had been considered the refer-
ence standard for the diagnosis of acute myocardial injury in
the past, but its utility was limited by lack of cardiac speciﬁcity
and its rapid clearance.
The high sensitivity and speciﬁcity of cardiac troponin as-
says confer great impact in the early diagnosis and risk strati-
ﬁcation in patients presenting with chest pain. The joint
committee of the European Society of Cardiology and the
American College of Cardiology issued the new criteria
acknowledging that elevations of cardiac troponins are funda-
mental for the diagnosis of myocardial infarction (Uettwiller-
Geiger et al., 2002).
Detection of cardiac troponin is not pathognomonic for
acute coronary syndrome but rather suggests myocardial in-
jury of any cause and may be found in non-coronary artery-
related conditions (Roongsritong et al., 2004). In addition to
their diagnostic value, elevated cardiac troponins have a strong
correlation with adverse cardiovascular outcome whether cor-
onary artery disease is present or not.
In this review article, we discuss the clinical applications of
troponins in various clinical settings and their role in the diag-
nosis and prediction of outcome in cardiac and non-cardiac
conditions.1.1. Diagnostic value of cardiac troponins
Cardiac troponin monitoring for detection of myocardial in-
jury has been designated the new standard for differentiating
the diagnosis of unstable angina and non-ST elevation myo-
cardial infarction (NSTEMI) in acute coronary syndrome
(ACS) patients (Braunwald et al., 2000).1.2. Acute myocardial infarction
Creatine kinase (CK)-MB was the gold standard marker of
myocardial necrosis used in the evaluation of acute coronary
syndromes (Roberts and Sobel, 1973). It is predominantly
located in myocardial cells and constitutes 1–3% of the total
CK found in skeletal muscle, and is also present in smaller
quantities in other tissues, such as intestine, diaphragm,
uterus, and prostate which limits its utility in clinical
practice.Recently, cardiac troponins have replaced the creatine ki-
nase (CK)-MB for both diagnosis and risk stratiﬁcation in
myocardial necrosis.
The early release kinetics of cTnI and cTnT allows detec-
tion at 3–6 h after symptom onset during MI and may remain
elevated for 7–14 days.
Previously, the diagnosis of myocardial infarction based on
the MONICA criteria includes the presence of suggestive chest
pain, pathological Q waves on electrocardiography and eleva-
tion of cardio-speciﬁc isoenzymes where creatine kinase (CK)-
MB is the gold standard marker (Tunstall-Pedoe et al., 1994),
while the new deﬁnition of MI by ESC/ACC/AHA is more
comprehensive and includes the clinical, electrocardiographic,
biochemical, imaging and pathological features suggestive of
myocardial necrosis (Alpert et al., 2000).
The recommended cut-off value for an elevated cardiac tro-
ponin is the 99th percentile of a control reference group at a
precision level of 610% coefﬁcient of variation (CV), which
is a measure of precision and is deﬁned as standard devia-
tion/mean (Alpert et al., 2000).
Current generation troponin T assay meets the level of pre-
cision as speciﬁed in the ACC/ESC deﬁnition, while different
manufacturers have used different antibodies raised against
different epitopes on cardiac troponin I, and there is no stan-
dardisation between the different troponin I assays, which
complicates their use. Thus at present, no troponin I assay
meets the ACC/ESC criteria for diagnosis of MI (French
and White, 2004).
Elevations of cTnI and cTnT are not sufﬁciently sensitive
at presentation in the ED and must be measured serially
over time to adequately exclude MI. Blood should be ob-
tained for testing on hospital admission, at 6–9 h and again
at 12–24 h if the earlier samples are negative and the clinical
index of suspicion is high (Alpert et al., 2000; Bassand et al.,
2007).
Troponin T has a short half-life of about 90 min, and per-
sistent elevation on day 3 or 4 reﬂects degradation of the con-
tractile elements which is a hallmark of irreversible cell injury
(Katus et al., 1989). With this deﬁnition, the detection of even
minor myocardial injury and the identiﬁcation of a high-risk
group of additional patients with acute coronary syndrome
is, therefore, appropriately classiﬁed as myocardial infarction
with early risk stratiﬁcation and management (Omland et al.,
2009). In addition to the diagnosis of MI the peak of troponin
level may provide information about the infarct size (Steen
et al., 2006).
1.3. Myocardial re-infarction
Detection of re-infarction is clinically important because it car-
ries an incremental risk for the patient. Re-infarction may
present special diagnostic difﬁculties, because an increase of
cardiac troponin is long-lasting, and when cardiac troponin
is persistently high, the timing of the initial myocardial damage
is difﬁcult to ascertain. If the ﬁrst sample on presentation has a
high cardiac troponin value, then for this reason a biomarker
with a shorter time course, such as CK-MB or myoglobin,
could be employed to clarify the timing of the infarct and to
detect the re-infarction (Alpert et al., 2000).
The re-infarction is deﬁned as recurrent symptoms occur-
ring within 18 h of myocardial infarction, with chest pain last-
ing more than 30 min and more than a 2 mm ST segment
6 M.A. Al-Otaiby et al.elevation or the presence of CK-MB rising above the upper
limit of the reference range or more than 50% of the baseline
value (French and White, 2004). Troponin I can also be used
for detecting re-infarction which is demonstrated by re-eleva-
tion of cTnI after it reaches the plateau (Apple and Murakami,
2005).
2. Detection of peri-procedural myocardial infarction
2.1. Detection of MI after percutaneous coronary intervention
(PCI)
Cardiac troponins are useful for the diagnosis of myocardial
infarction and myocardial necrosis (Mair et al., 1991). They
are more sensitive than CKMB for the detection of minor
damage missed by conventional markers which are prognosti-
cally important (La Vecchia et al., 1996; Shyu et al., 1998;
Harrington et al., 1995). The reported incidence of troponin
T or I release after percutaneous coronary intervention (PCI)
ranges between 13% and 44%, with the incidence higher after
stenting (La Vecchia et al., 1996; Ravkilde et al., 1994; Karim
et al., 1995; Saadeddin et al., 2001). Any elevation post-
procedure is indicative of cardiac injury which raises the
concern about potential problems arising from using overly
sensitive tests to detect myocardial injury after PCI (Pierpont
and McFalls, 2009). However, the diagnosis of a procedure-re-
lated MI needs a three-fold increase from the normal baseline
value.2.2. Diagnosis of myocardial infarction after cardiac surgery
Perioperative MI after CABG, as deﬁned by new Q waves on
the post-operative ECG, occurs in 4–5% of patients and the
cardiac markers are more common than Q waves, occurring
in 62–90% of patients because most of the damage which oc-
curs during CABG is sub-endocardial injury and the transmu-
ral infarction may require 5–10 times the upper limit of normal
CK-MB. Therefore, for myocardial infarction after cardiac
surgical procedures, a ﬁve-fold increase from the baseline in
biomarkers is recommended, along with associated ﬁndings,
such as new Q waves (Righetti et al., 1977).
As we know from literature, predisposing factors for peri-
operative myocardial infarction (PMI) in cardiac surgery pa-
tients include: incomplete revascularization, diffuse disease,
inadequate myocardial protection during surgery, transient
hypotension, left ventricular hypertrophy, prior PCI before
CABG, recent MI less than one week, and emergency CABG
(Van Lente et al., 1989). The guidelines state: Biomarker val-
ues more than ﬁve times the 99th percentile of the normal ref-
erence range during the ﬁrst 72 h following CABG when
associated with the appearance of new pathological Q-waves
or new left bundle-branch block (LBBB), angiographically-
documented new graft or native coronary artery occlusion,
or imaging evidence of new loss of viable myocardium, should
be considered as diagnostic of a CABG-related myocardial
infarction (Adams et al., 1994).
Although creatine kinase MB exhibited the best diagnostic
association with the presence of perioperative myocardial
infarction, there is a poor correlation between changes in the
cardiac biomarker activity and the ultimate evidence of post-
CABG MI at autopsy (Thygesen et al., 2007).Cardiac troponin levels are detectable in nearly all patients
after CABG in the absence of a clinically documented MI. In
spite of an excellent negative predictive value of cardiac tropo-
nins for the detection of myocardial injury after CABG, there
is a degree of heterogeneity of optimal cut-off points for cTn
measurement to predict the risk but a single cut-off point can-
not be recommended to make a precise diagnosis of MI (Botha
et al., 2004; Costa et al., 2001).
Carrier et al. (2000) illustrated the diagnostic value of tro-
ponin elevations in a study of 590 patients in whom a cTnT
concentration >3.4 lg/L at 24 h after CABG correlated best
with a perioperative MI, as deﬁned by new Q waves on the
ECG and CK-MB >100 IU/L within 48 h after surgery with
high sensitivity and speciﬁcity and positive and negative pre-
dictive values exceeding 90%.
2.3. Diagnosis of MI after non-cardiac surgery
Perioperative ischemic events were mostly asymptomatic; they
occur most commonly in the post-operative period and carry a
high mortality rate (Mangano, 1990).
The lack of standardisation of the surgical procedures and
variety of the related surgical risk creates different approaches
for everymedical institution for perioperative cardiac assessment.
Many clinicians use electrocardiography, echocardiography
and cardiac enzymes in their approach. However, uninterpret-
able ECGs in many perioperative conditions and low-sensitive
transthoracic echocardiography in the diagnosis of new myo-
cardial infarctions make those modalities insufﬁcient in such
conditions (Adams et al., 1994; Eisenberg et al., 1992).
The false positive elevation of CK-MB is more frequent
than true elevation, therefore, limiting its diagnostic value
and leading to putting a major weight on cardiac troponins,
which are sensitive and speciﬁc if their level is interpreted in
the context of a clinical condition and the incremental mea-
surements taken rather than a single absolute value. Where
the cardiac troponin I proved to be a very sensitive diagnostic
tool, it was able to detect minor myocardial injury that was
not detected by other traditional techniques. Interestingly,
cTnT showed a strong positive predictive power for major
in-hospital cardiac complications (Lee et al., 1996).
The importance of early diagnosis of perioperative MI im-
plies rapid access to intensive care facilities for patients with
acute myocardial infarction and signiﬁcant reduction of the
short-term mortality (Udvarhelyi et al., 1992).
Troponins are ideal for diagnosing perioperative MI after
non-cardiac surgery. The same cut-off levels used to diagnose
an acute MI should be used to detect perioperative injury in
such patients.
2.4. Other causes of elevated cardiac troponin
Troponin elevations have been reported in a variety of clinical
conditions other than coronary artery disease (Table 1). In a
series of 21 subjects, Bakshi et al. (2002) reported tachycardia
in 28%, pericarditis in 10%, heart failure in 5% and strenuous
exercise in 10%. Elevated cardiac troponins have been used to
detect structural heart disease, such as cardiomyopathies, myo-
pericarditis, tachyarrhythmias, pulmonary embolism and high-
dose chemotherapy due to minor myocardial injury in those
conditions (Korff et al., 2006). In heart failure patients the ele-
vated troponin levels occur in approximately 49% of the cases,
Table 1 Causes of elevated cardiac troponin levels.
Coronary artery related
Atherosclerosis or emboli
Coronary spasm
Coronary dissections
Post-coronary interventions
Myocardial injury or strain
Myocarditis or myopericarditis
Tachyarrhythmias
Toxic drugs (e.g., anthracyclines)
Pulmonary embolism
Congestive heart failure
Cardiomyopathies (e.g., inﬁltrative diseases)
Sepsis
Exercise
Pheochromocytoma
Traumas
Cardiac surgery
Chest trauma
Direct current deﬁbrillations
Radiofrequency ablations
False positive and laboratory errors
The clinical signiﬁcance of cardiac troponins in medical practice 7which is attributed to multiple mechanisms including excessive
wall tension, sympathetic stimulation, and activation of rennin
angiotensin aldosterone system, oxidative stress and inﬂamma-
tory mediators release (Horwich et al., 2003; Jeremias and
Gibson, 2005). While in critically ill patients, especially septic
shock individuals, the troponin rise occurs in 50–85% and
may indicate disease severity rather than ischemic events
because several papers addressed this issue and noticed that
the coronary blood ﬂow and myocardial lactate extraction in-
crease, while the oxygen availability to myocardium is pre-
served, and microvascular dysfunction and myocytotoxic
effects of endotoxin, cytokines, reactive oxygen radicals and al-
tered membrane permeability may have a role (Cunnion et al.,
1986; Dhainaut et al., 1987; Lim et al., 2006a,b; Ammann
et al., 2003; van Bockel et al.,2003). The central nervous system
conditions the elevated troponin found in 27% of acute stroke
and 20% of subarachnoid haemorrhage cases and this may be
attributed to an imbalance in the autonomic nervous system
resulting in an excess of sympathetic activity and an increased
catecholamine effect on myocardial cells (Jeremias and
Gibson, 2005; Tung et al., 2004). Troponin elevation was ob-
served in more than 53% of patients in the absence of clinical
ischemia and was thought to be due to a silent myocardial in-
jury, increased left ventricular mass or impaired renal troponin
excretion (Jeremias and Gibson, 2005).
A false positive result was observed in several conditions
ranging from 0.17% to 40%, and Bakshi et al. (2002) found
no identiﬁable cause in 47% of patients with elevated troponin
and normal coronaries. Common causes of false positive tro-
ponin include: heterophilic antibodies, rheumatoid factor, ﬁ-
brin clots, micro-particles and analyzer malfunction. This
error can be avoided by antibody blocking agents, use of clot
activators, repeating the centrifugation, adding super serum
and running quality-controlled samples after each mainte-
nance check of the analyzer (Roongsritong et al., 2004; Beyne
et al., 2000).Patients with a low pre-test probability of CAD will most
likely not derive any beneﬁt from a treatment strategy aimed
at coronary thrombosis (Jeremias and Gibson, 2005; Lim
et al., 2006b).
2.4.1. Prognostic value of elevated cardiac troponins
Cardiac troponins play a major role in predicting the cardiac
events in several situations where their elevated levels are fre-
quently observed.
2.4.2. Cardiac troponins in acute coronary syndrome
Troponin positivity in patients with acute coronary syndrome
implies a signiﬁcantly worse prognosis and indicates a response
with a signiﬁcant reduction of death or non-fatal myocardial
infarction to glycoprotein IIb/IIIa inhibitors.
Elevated troponin levels may point to an increased preva-
lence of signiﬁcant coronary disease, multi-vessel coronary dis-
ease, visible thrombus, suboptimal coronary ﬂow or reduced
left ventricular systolic function ( Anonymous, 1997; Rao
et al., 2003).
In a CAPTURE trial, as late as 5 days’ randomization to
abciximab led to a 60% reduction of death and non-fatal
myocardial infarction (Anonymous, 1997). A PRISM study
showed that patients with elevated troponin at a mean of
8.4 h after symptoms started had death or MI in 4.3%
compared to 13% in those with positive troponin and had
not received tiroﬁban (Anonymous, 1998). While in a
PARAGON-B trial sub-study, patients with a cardiac
troponin T of more than 0.1 ng/ml within 24 h of symptom
onset were given Lamiﬁban which led to a 42% relative reduc-
tion of death or MI at 30 days compared to those with negative
troponins (Newby et al., 2001).
TACTIC-TIMI 18 sub-study reported around 4% of pa-
tients who satisﬁed the criteria for acute coronary syndrome
and had positive cardiac troponin had no angiographic ﬂow
limiting epicardial coronary disease which might suggest a
false positive troponin test, but the 6 months death, myocar-
dial infarction and re-hospitalization were signiﬁcantly higher
in troponin-positive patients than those with no signiﬁcant
coronary artery disease and negative troponin (Wong et al.,
2002).
Interestingly, it was found that even in patients presenting
to emergency departments without chest pain, an elevated car-
diac troponin was signiﬁcantly associated with death and myo-
cardial infarction at one year (Swinkels et al., 2006). On the
other hand, positive troponin T in stable coronary artery dis-
ease predicts the incidence of cardiovascular death and heart
failure but not myocardial infarction (Omland et al., 2009),
while the role of elevated troponins in patients without acute
coronary syndrome still debated the data from recent study
that showed higher mortality (Wong et al., 2007).
2.4.3. Cardiac troponins and prediction of post-percutaneous
coronary intervention (PCI) events:
As many as 48% of coronary angioplasty patients have detect-
able troponin levels post-PCI (Cantor et al., 2002).
Multiple studies showed that minor troponin elevations
post-successful coronary angioplasty were not associated with
any adverse clinical outcome during the long-term follow up
(Garbarz et al., 1999).
In contrast, studies evaluating the long-term follow up of
patients with creatine phosphokinase (CK-MB) elevation after
8 M.A. Al-Otaiby et al.PCI suggested that post-procedural enzyme elevation is associ-
ated with a worse clinical outcome (Harrington et al., 1995;
Abdelmeguid et al., 1996).
On reviewing literature, many data suggest that there is
probably no association between minor myocardial injury
occurring after successful angioplasties and late adverse car-
diac events, particularly if CK-MB is negative (Okmen et al.,
2006).
An observational study from the Mayo Clinic found that
the pre-procedural cardiac troponin T elevation is a more
powerful predictor of post-PCI cardiac events than post-
procedural levels (Prasad et al., 2008).
A meta-analysis of 15,581 patients in twenty studies was
performed by Nienhuis MB and colleagues found troponin
elevation in 32.9% of the patients and a 1.1% higher mortality
compared with the non-troponin elevated group (Nienhuis
et al., 2008). A recent meta-analysis of ﬁfteen studies with a
total of 7578 patients found 15% of them ﬁll the new guide-
lines deﬁnition of MI with increased cardiac events up to
18 months (Testa et al., 2009).
Many conﬂicting data in this issue make the need for ran-
domized trials instead of small or observational studies to re-
solve these variations in the results.
2.4.4. Cardiac troponins and coronary bypass grafting (CABG)
Almost all patients undergoing cardiac surgery will have
detectable cardiac troponins. The level of rise of troponins par-
allels the level of injury occurred during that surgery. It is,
therefore, useful to remember a time course of cardiac tropo-
nin elevation in those with perioperative myocardial infarc-
tion, which peaks 8–16 h post-surgery (Katus et al., 1991).
Whether the patients had preoperatively-elevated readings
of troponins is an important factor to consider when analyzing
post-operative levels. Collectively, higher levels of troponin
after surgery imply a worse outcome compared to those with
undetectable or low level troponins (Force et al., 1990).
Pre-operative elevation of cardiac troponin in more than
0.1 ng/ml within 24 h before cardiac surgery is the strongest
predictor of morbidity, mortality and a longer hospital stay
(Swaanenburg et al., 1998; Espinoza et al., 1974; Jain, 1992;
Muehlschlegel et al., 2009).
Pre-operative elevation of cardiac troponin T in more than
0.02 ng/ml identiﬁes a sub-group of patients with a longer
intensive care unit stay and higher in-hospital morbidity
(Hamm et al., 1992).
After elective open heart surgery, a single measurement of
cardiac troponin T of more than 0.46 mg/l at 48 h after cardiac
surgery was an independent predictor of both short-term and
long-term mortality and morbidity (Lehrke et al., 2004).
The negative predictive value of cardiac troponin T below
3.9 mg/l at 24 h of open cardiac surgery is more than 90%
(Bonnefoy et al., 1998).
2.4.5. Cardiac troponins and heart failure
The usefulness of cardiac troponins in prognosis of acute heart
failure trials is limited by the fact that serial (rather than one)
estimations of cardiac troponins are needed to rule out the
possibility of acute myocardial infarction. However, after mul-
tivariate adjustment, there was a signiﬁcant persistent dose-
response relationship between cardiac troponin and mortality,
i.e., the higher the level of troponin, the higher the mortality.In patients with chronic heart failure, the fate of high car-
diac troponin is unknown in view of scanty data.
In heart failure patients, elevated troponin is associated
with the risk of death and re-hospitalization regardless of
underlying cause and the three-year survival is about 29%
(Setsuta et al., 1999; Perna et al., 2002).
2.4.6. Cardiac troponins and renal failure
Cardiac troponin T is detectable in the blood of patients with
chronic kidney disease whether or not dialyzed. This is a true
detection and is not cross-reactivity with skeletal troponin.
An elevated cardiac troponin T more than 0.l mg/l is
strongly associated with all cause mortality in haemodialyzed
patients as shown in many trials (McLaurin et al., 1997;
Dierkes et al., 2000; Gabr et al., 2004).
In renal failure elevated cardiac troponin is associated with
a two- to ﬁve-fold increase in mortality but reduced its sensitiv-
ity and speciﬁcity in suspected CAD (Apple et al., 2002;
Goldmann et al., 2001; Van Lente et al., 1999).
2.4.7. Cardiac troponins in non-cardiac patients in intensive care
units
Critically ill patients who require staying in an intensive care
unit are a heterogeneous group of patients who are ill for a
variety of heterogeneous diseases. Thus, estimation of cardiac
troponins and their signiﬁcance in these patients are heteroge-
neous (Guest et al., 1995).
The prevalence of raised cardiac troponins in an ICU gen-
erally ranges between 15% and 70% and the majority of these
critically ill patients (about 70%) are not having ﬂow-limiting
coronary artery disease, as demonstrated by stress echocardi-
ography or autopsy (Ammann et al., 2003).
Forty-two percent of patients needing to be transferred to
ICU are troponin positive but myocardial infarction could
be documented only in 50% of them. On the other hand,
around 12% of patients in ICU will have a rise in their cardiac
troponin, and 75% of them will meet the criteria for myocar-
dial infarction (Lim et al., 2006b).
Cardiac patients with known coronary artery disease, who
have been admitted for a medical reason and became critically
ill, will have a signiﬁcantly higher in-hospital mortality if they
have a high cardiac troponin level (Kollef et al., 1997).
Among critically ill medical patients, the clinical deteriora-
tion of cardiac dysfunction is an independent predictor of a
signiﬁcantly higher mortality, but an isolated elevation of car-
diac troponin is not (King et al., 2005; Favory and Neviere,
2006; Keller et al., 2009).
The higher mortality noted in those critically ill ICU pa-
tients with elevated cardiac troponin is due to the fact that they
are sicker (Keller et al., 2009).
3. Conclusion
Troponins are highly sensitive and speciﬁc cardiac markers
which play a major role in the diagnosis and risk stratiﬁcation
of coronary artery disease and the interpretation of their re-
sults should be in the clinical context. On the other hand,
the elevation of troponin levels in the absence of coronary ar-
tery disease is of little diagnostic value but may be helpful in
anticipating the outcome but does not dictate which type of
management is appropriate.
The clinical signiﬁcance of cardiac troponins in medical practice 9Elevated troponin in patients with coronary artery disease
who presented with acute coronary syndrome may indicate
high risk and predict the beneﬁt from aggressive therapy, while
non-thrombotic causes derive no beneﬁt from aggressive ther-
apy in low-risk patients.
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